Chronos Wealth Management LLC Has $4.85 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Chronos Wealth Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,536 shares of the company’s stock after selling 611 shares during the quarter. Johnson & Johnson makes up 2.5% of Chronos Wealth Management LLC’s holdings, making the stock its 18th biggest holding. Chronos Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,850,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Apollon Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 20.7% during the fourth quarter. Apollon Wealth Management LLC now owns 105,500 shares of the company’s stock valued at $15,257,000 after purchasing an additional 18,082 shares in the last quarter. Vest Financial LLC boosted its stake in shares of Johnson & Johnson by 10.1% during the fourth quarter. Vest Financial LLC now owns 366,147 shares of the company’s stock valued at $52,952,000 after purchasing an additional 33,658 shares in the last quarter. SC&H Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson by 17.0% during the fourth quarter. SC&H Financial Advisors Inc. now owns 1,959 shares of the company’s stock valued at $283,000 after purchasing an additional 285 shares in the last quarter. Cidel Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 2.8% during the fourth quarter. Cidel Asset Management Inc. now owns 16,338 shares of the company’s stock valued at $2,363,000 after purchasing an additional 440 shares in the last quarter. Finally, Conning Inc. raised its position in shares of Johnson & Johnson by 7.1% during the fourth quarter. Conning Inc. now owns 229,267 shares of the company’s stock worth $33,157,000 after acquiring an additional 15,180 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Up 1.3 %

NYSE JNJ opened at $156.18 on Wednesday. The company has a market cap of $376.02 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The business has a 50 day moving average price of $147.40 and a 200-day moving average price of $156.04. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.